Alkermes

NCT01218958

ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

NCT01218971

ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)

NCT01218997

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

NCT00156923

ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults

NCT00156936

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

NCT00127634

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

NCT00157339

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

NCT00325364

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

NCT00355849

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

NCT00356109

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

NCT00391209

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

NCT00437112

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

NCT00501631

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

NCT00678418

ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence

NCT00834080

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

NCT01180647

Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

NCT01436032

Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery

NCT01469039

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

NCT01626456

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

NCT01895452

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

NCT02085135

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

NCT02141399

A Long-Term Safety Study of ALKS 5461

NCT02158533

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

NCT02158546

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

NCT02218008

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

NCT02110264

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

NCT02537574

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

NCT02634307

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

NCT02634346

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

NCT02669758

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02694328

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

NCT02696434

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02873208

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT03093324

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

NCT03187769

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

NCT03188185

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

NCT03201757

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

NCT03345979

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCT03610048

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03711318

Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

NCT04987229

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

NCT05303064

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder